9II Stock Chart & Stats
€0.03
<€0.01(3.03%)
At close: 4:00 PM EDT
€0.03
<€0.01(3.03%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)666.00
Market Cap
€9.42M
Enterprise Value€100.39M
Total Cash (Recent Filing)€51.59M
Total Debt (Recent Filing)€6.02M
Price to Earnings (P/E)―
Beta9.63
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding277,487,200
10 Day Avg. Volume0
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.95
Price to Sales (P/S)6.14
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€2.31M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth and improving commercial traction indicate that Biovica is increasing adoption of its diagnostics offering. Continued top-line expansion can support operating leverage over time, broaden the customer base, and create a stronger foundation for future progress toward profitability.
Low LeverageVery low leverage gives Biovica greater financial flexibility than a highly indebted development-stage company. Limited debt obligations can reduce balance-sheet pressure, preserve options for investment, and provide more capacity to manage continued commercialization and research spending.
Improving Losses And Cash BurnThe reduction in net losses and improvement in cash burn suggest progress in controlling the economic burden of the business, even though the company remains unprofitable. If sustained, this trend could extend its funding runway and improve the path toward eventual operating breakeven.
Bears Say
Persistent UnprofitabilityNegative gross profit and deeply negative net margins show that current revenue does not cover the cost base, making profitability highly dependent on substantial improvement in economics or scale. This weak earnings foundation can limit self-funded growth and prolong reliance on external capital.
Heavy Cash BurnSubstantial operating and free-cash-flow outflows indicate that Biovica is consuming cash rather than funding operations internally. Persistent burn can reduce financial flexibility, require additional financing, and make the company more vulnerable if revenue growth does not translate into better margins.
Declining Equity And Funding DependenceThe decline in equity reflects the cumulative effect of continued losses consuming capital and reinforces Biovica’s dependence on its balance sheet to fund operations. Without a faster improvement in profitability, this erosion can constrain investment capacity and increase future financing needs.
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €9.42M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Dec 17, 2026 which is in 46 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Sep 09, 2026. The company reported -€0.006 earnings per share for the quarter.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 277,487,200 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biovica International AB Class B
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Technical Analysis
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―
Sprint Bioscience AB
―
Fluicell AB
―